Climb Biotherapeutics, Inc. Insider Trading
CLYM
Insiders bought 755K and sold $2.65M on the open market.
All of the selling was scheduled in advance under 10b5-1 plans.
Get an email when CLYM's executives or directors buy, or make a large sale outside a plan.
Trades · last 2 years
| Date | Insider | Trade | Shares | Price | Value | Of their stake | Filing |
|---|---|---|---|---|---|---|---|
| Sep 15 | Stephen Basil Thomas Director | Sold10b5-1 plan | 100,000 | $13.67 | $1.37M | 18% | Form 4 |
| Jun 29 | Aoife Brennan President and CEO | Sold10b5-1 plan | 30,902 | $13.17 | 407K | 26% | Form 4 |
| Feb 25 – 26 | Stephen Basil Thomas Director | Sold10b5-1 plan 2 parts | 50,000 | $7.00 average | 350K | 24% | Form 4 |
| Feb 12 – 13 | Stephen Basil Thomas Director | Sold10b5-1 plan 2 parts | 100,000 | $5.29 average | 529K | 33% | Form 4 |
| Jan 5 | RA Capital Healthcare Fund LP Large holder | Bought | 7,111 | $3.50 | 25K | 0.2% | Form 4 |
| Dec 11, 2025 – Dec 12, 2025 | Peter Kolchinsky Director | Bought 2 parts | 314,561 | $2.40 average | 755K | 10% | Form 4 |
| Jun 30, 2025 | Aoife Brennan President and CEO | Sold10b5-1 plan | 20,618 | $1.22 | 25K | 30% | Form 4 |
| Jun 20, 2025 | Emily Pimblett SVP, Finance & CAO | Sold10b5-1 plan | 1,242 | $1.24 | 2K | 6.2% | Form 4 |
| Mar 20, 2025 | Emily Pimblett SVP, Finance & CAO | Sold10b5-1 plan | 1,199 | $1.31 | 2K | 7.3% | Form 4 |
| Dec 19, 2024 | Emily Pimblett Chief Accounting Officer | Sold10b5-1 plan | 1,235 | $2.02 | 2K | 9.8% | Form 4 |
- Sep 1510b5-1 planStephen Basil ThomasDirector · sold 100,000 at $13.67$1.37M18% of stake
- Jun 2910b5-1 planAoife BrennanPresident and CEO · sold 30,902 at $13.17407K26% of stake
- Feb 25 – 2610b5-1 planStephen Basil ThomasDirector · sold 50,000 at avg $7.00350K24% of stake
- Feb 12 – 1310b5-1 planStephen Basil ThomasDirector · sold 100,000 at avg $5.29529K33% of stake
- Jan 5RA Capital Healthcare Fund LPLarge holder · bought 7,111 at $3.5025K0.2% of stake
- Dec 11, 2025 – Dec 12, 2025Peter KolchinskyDirector · bought 314,561 at avg $2.40755K10% of stake
- Jun 30, 202510b5-1 planAoife BrennanPresident and CEO · sold 20,618 at $1.2225K30% of stake
- Jun 20, 202510b5-1 planEmily PimblettSVP, Finance & CAO · sold 1,242 at $1.242K6.2% of stake
- Mar 20, 202510b5-1 planEmily PimblettSVP, Finance & CAO · sold 1,199 at $1.312K7.3% of stake
- Dec 19, 202410b5-1 planEmily PimblettChief Accounting Officer · sold 1,235 at $2.022K9.8% of stake
Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.
Peers
Pharmaceutical Preparations · Pick stocks to compare with CLYM
Held by ETFs
CLYM is in 15 US ETFs. The largest of them, with CLYM's weight in each:
iShares Russell 2000 Growth ETFIWO0.01%of the fund
State Street SPDR S&P Biotech ETFXBI0.11%of the fund
Vanguard U.S. Momentum Factor ETFVFMO0.12%of the fund
Vanguard Russell 2000 Growth ETFVTWG0.01%of the fund
iShares Micro-Cap ETFIWC0.09%of the fund
Fidelity Fundamental Small-Mid Cap ETFFFSM0.11%of the fund
Spot a number that looks wrong? Check it in CLYM's SEC filings or
Download this analysis as a PDF (Pro)
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing CLYM
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.